Tuesday 13 October 2026 Export CAPR’s income statement to Excel — free account

Capricor Therapeutics, Inc.

Capricor Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $22.3 million, down 11.5% from fiscal 2023. In the quarter to June 2026, revenue fell 7.92%, EPS fell 22.8% and free cash flow fell 72.9%, each against the same quarter a year earlier.

6.95 0.52 −6.96%

Follow CAPR

Alert me

Market cap: $434.3M
P/E: 0.0×
Fwd P/E: −13.2×
Dividend yield: —
F-score: 4/9
Altman Z: 10.32
Beneish M: −2.61
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 8.37

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	3	1	2	4	—	—	—	—

Insider Ownership 9.11%

Capital & Financial Ratios $m

Market Cap 434.30

Revenue 22.27

Net Income (129.42)

Free Cash Flow 130.91

Net Debt (237.93)

Current Ratio 7.35

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (13.20)

P/S ratio 19.43

P/B ratio 1.76

Past 5Y EPS Growth —

This Y EPS Growth 33.05%

Next Y EPS Growth 3.28%

Next Y revenue growth (97.35%)

Next 5Y EPS Growth 50.75%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 55.04%

10-year low 10-year high

P/B against its own 10 years 5.53%

10-year low 10-year high

EV/Sales against its own 10 years 17.10%

10-year low 10-year high

EV/FCF against its own 10 years 8.42%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	39	152	318	238
Receivables	10	10	0	—
Inventory	—	—	—	—
Other	—	—	—	—
	51	163	323	242

	2023	2024	2025	Q'26
Payables	6	3	2	3
ST’ Debt	—	—	—	—
Other	—	—	6	—
	31	21	36	33

Compound Annual Growth %

	10y	5y	3y
Sales	16.62%	85.83%	349.69%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	61.08%	196.04%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’24	5	4	2	11	22
’23	3	4	6	12	25
’22	—	—	2	1	3
’21	0	0	—	0	0
’20	0	0	0	0	0
’19	0	0	0	0	1

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(29)	(31)	—	—	—
’25	(6)	(20)	(20)	(24)	(70)
’24	(1)	(12)	(12)	(15)	(40)
’23	4	(9)	(9)	(12)	(26)
’22	24	(7)	(6)	(7)	5
’21	(3)	(5)	(3)	(6)	(17)
’20	(1)	(2)	(3)	(4)	(10)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(40)	(37)	—	—	—
’25	(8)	(22)	(24)	232	179
’24	(2)	(12)	(12)	78	52
’23	4	(10)	(9)	(12)	(28)
’22	23	(7)	(7)	(8)	2
’21	(3)	(5)	(4)	(6)	(18)
’20	(1)	(2)	(3)	(4)	(11)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.59)	(0.70)	—	—	—
’25	(0.53)	(0.57)	(0.54)	(0.62)	(2.26)
’24	(0.31)	(0.35)	(0.38)	(0.16)	(1.15)
’23	(0.31)	(0.29)	(0.25)	(0.02)	(0.83)
’22	(0.32)	(0.29)	(0.26)	(0.31)	(1.18)
’21	(0.23)	(0.21)	(0.17)	(0.26)	(0.87)
’20	(0.30)	(0.23)	(0.20)	(0.21)	(0.88)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	18.80	6.30	3.10	1.00	0.88	2.75	2.56	2.68	3.52	4.30	Analyst estimates 2026–2028 Powerpack
	High	54.00	42.50	22.90	8.85	12.32	8.40	6.58	8.22	23.40	40.37
People
People	Employees	40	40	22	16	26	48	74	102	160	231
	Revenue/emp, $m	0.10	0.07	0.08	0.06	0.01	0.01	0.03	0.25	0.14	0.00
Income, $m
Income, $m	Revenue	4	3	2	1	0	0	3	25	22	—
	Gross margin, %	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	—
	EBT	(19)	2	(15)	(8)	(14)	(20)	(29)	(22)	(40)	(105)
	EBT margin, %	(470.33)	91.19	(908.88)	(760.38)	(4,401.22)	(8,175.79)	(1,137.35)	(88.52)	(181.70)	0.00
	Net income	(19)	2	(15)	(8)	(14)	(20)	(29)	(22)	(40)	(105)
	Depreciation	0	0	0	0	0	0	1	1	1	2
Per share, $
Per share, $	Revenue	2.16	1.15	0.57	0.27	0.02	0.01	0.10	0.94	0.63	0.00
	Earnings	(10.10)	1.00	(5.20)	(2.06)	(0.88)	(0.87)	(1.18)	(0.83)	(1.15)	(2.26)
	Cash flow	(7.79)	(6.14)	(4.71)	(1.84)	(0.65)	(0.73)	0.20	(0.96)	(1.14)	(1.50)
	Capex	(0.10)	(0.01)	7.71	0.81	(0.04)	(0.05)	(0.14)	(0.08)	2.62	5.35
	Free cash flow	(7.90)	(6.15)	3.00	(1.03)	(0.68)	(0.78)	0.06	(1.03)	1.48	3.85
	Book value	(2.16)	4.84	1.57	1.84	1.81	1.36	0.48	0.84	4.13	6.58
	Shares, m	2	2	3	4	16	23	25	27	35	46
Valuation, ×
Valuation, ×	P/E	0.00	52.33	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—
	P/S	11.83	13.66	7.21	4.73	172.12	223.49	34.30	5.45	21.82	—
	P/B	0.00	3.24	2.61	0.69	1.89	2.16	8.02	6.07	3.34	—
	EV/Sales	10.92	18.60	19.49	12.33	112.70	155.13	24.42	4.44	15.66	—
	EV/FCF	(2.98)	(3.48)	3.69	0.65	(4.60)	(2.61)	43.23	(4.04)	6.67	—
Cash, $m
Cash, $m	Operating cash flow	(14)	(14)	(14)	(7)	(10)	(17)	5	(26)	(40)	(70)
	Capex	0	0	23	3	(1)	(1)	(3)	(2)	92	249
	Free cash flow	(15)	(14)	9	(4)	(11)	(18)	2	(28)	52	179
Balance, $m
Balance, $m	Working capital	13	14	7	10	31	32	19	20	142	287
	Total debt	14	3	3	3	0	6	5	—	—	—
	Net debt	(4)	(11)	(4)	(7)	(33)	(35)	(41)	(39)	(152)	(318)
	Shareholders’ equity	(4)	11	5	7	28	31	12	23	145	306
Returns, %
Returns, %	ROA	(108.03)	13.89	(119.05)	(75.06)	(59.73)	(52.73)	(63.48)	(40.96)	(35.31)	(39.91)
	ROIC	0.00	0.00	(2,130.18)	(1,463.42)	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	747.04	67.32	(191.78)	(133.42)	(77.95)	(67.23)	(134.49)	(129.63)	(48.16)	(46.56)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2024 · latest quarter Dec 2024

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ASMB Assembly Biosciences, Inc.	$479.1M	22.3×	— (loss-making)	+38.94% (above 0%: growing)	n/m	+7.58% (above 0%: growing)	100.00%	(47.44%)	Compare
YDES YD Bio Limited	$476.8M	—	—	—	—	—	—	—	Compare
RZLT Rezolute, Inc.	$471.1M	— (loss-making)	—	—	n/m	+40.23% (above 0%: growing)	0.00%	0.00%	Compare
ENTX Entera Bio Ltd.	$462.4M	— (loss-making)	— (loss-making)	+200.00% (above 0%: growing)	n/m	−108.86% (below 0%: shrinking)	0.00%	0.00%	Compare
TECX Tectonic Therapeutic, Inc.	$456.1M	— (loss-making)	—	—	n/m	−46.69% (below 0%: shrinking)	0.00%	0.00%	Compare
CAPR Capricor Therapeutics, Inc.	$455.2M	— (loss-making)	— (loss-making)	−7.92% (below 0%: shrinking)	n/m	−72.88% (below 0%: shrinking)	100.00%	0.00%
PRTA Prothena Corporation plc	$453.8M	— (loss-making)	188×	−77.15% (below 0%: shrinking)	n/m	+44.64% (above 0%: growing)	100.00%	(2,089.21%)	Compare
DMAC DiaMedica Therapeutics, Inc.	$449.2M	— (loss-making)	— (loss-making)	—	n/m	−6.75% (below 0%: shrinking)	0.00%	0.00%	Compare
EDIT Editas Medicine, Inc.	$445.4M	— (loss-making)	— (loss-making)	+232.31% (above 0%: growing)	n/m	+40.72% (above 0%: growing)	100.00%	(156.05%)	Compare
Median of peers	$459.2M	—	—	+119.47%	—	+7.58%	0.00%	0.00%

All 614 Biotechnology stocks →